Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa

AbbVie

Status and phase: Completed; Phase 3

Conditions: Hidradenitis Suppurativa

Treatments: Drug: adalimumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT02904902

M15-573

Details and patient eligibility

About

This study investigates efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with moderate to severe hidradenitis suppurativa (HS).

Full description

Prior to initiation of this study, global Phase 2b study and pivotal Phase III studies were completed in the Western countries and market authorization of adalimumab was approved in United States (US) and European Union (EU) for the treatment of subjects with HS. The differences between this study and global studies include sample size, study design, duration, and race.

Enrollment: 15 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant must have a diagnosis of HS;
• Participant must have any HS symptom at least 6 months prior to Baseline;
• HS lesions must be present in at least 2 distinct anatomic areas, one of which must be Hurley Stage II or Hurley Stage III;
• Participant must have stable HS for at least 2 months (60 days) prior to Screening and also at the Baseline visit;
• Participant must have a total abscess and inflammatory nodule (AN) count of greater than or equal to 3 at the Baseline visit.

Exclusion criteria

• Prior treatment with adalimumab or other anti-tumor necrosis factor (TNF) therapy or participation in adalimumab trial;
• Any other active skin lesion or condition that may interfere with assessment of HS;
• Participants received antibiotic treatment for HS within 28 days prior to the Baseline visit other than those allowed per protocol. Participant on permitted oral antibiotic treatment (doxycycline or minocycline only) for HS who have not been on a stable dose for at least 28 days prior to the Baseline visit;
• Participants received prescription topical therapies for the treatment for HS within 14 days prior to the Baseline visit;
• Participants received systemic non-biologic therapies with potential therapeutic impact for HS less than 28 days prior to the Baseline visit;
• Participants received oral concomitant analgesics (non-opioids and opioids) for HS-related pain within 14 days prior to the Baseline visit.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

Adalimumab

Experimental group

Description:

Open-label adalimumab 160 mg subcutaneous injection at Week 0 (Baseline), 80 mg at Week 2, and 40 mg every week starting at Week 4. After Week 52, Participants who consent to receive the 80 mg eow dose, will switch from 40 mg ew to 80 mg eow at Week 0x (80 mg eow period until the end of the study).

Treatment:

Drug: adalimumab